Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

Aclaris Therapeutics ---ACRS

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Biotechmaster, Sep 12, 2019.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    207
    Likes Received:
    5
    $2++ coming and going wayyy higher on Partnership news and Phase 3 results
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    207
    Likes Received:
    5
    ACRS..Eskata approval likely next week guys , 10 months review timeline like in USA so approval should come next week


    Price $1.17 ...Market cap $48 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79

    Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
    https://cipher.investorroom.com/201...Solution-Accepted-for-Review-by-Health-Canada

    Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ("Aclaris") in April 2018.

    A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern. A-101 40% was approved by the FDA in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata™.
     
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    207
    Likes Received:
    5
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    207
    Likes Received:
    5
    William Blair sees 'significant value disconnect' in Aclaris Therapeutics William Blair analyst Tim Lugo maintains an Outperform rating on Aclaris Therapeutics after the company announced the divestiture of worldwide rights for Rhofade to EPI Health for up to $55M. The analyst says the deal value compares well with his previously estimated net present value for the Rhofade program of $65M. The divestiture is a first step in management extracting value from its commercial portfolio as the company has signaled additional partnerships and divestitures, Lugo tells investors in a research note. He continues to see a "significant value disconnect" with Aclaris shares trading at less than half of cash. The analyst sees "some promising early-stage assets, and near-term potential for strategic partnerships."

    Read more at:
    https://thefly.com/landingPageNews.php?id=2974505
     

Share This Page